Hitachi reclaims Summit gamma cameras
Hitachi Medical of Tokyo will use the RSNA meeting as a springboardin its plan to reenter the nuclear medicine market with directsales and marketing of digital gamma cameras it has manufacturedfor Summit Nuclear. Hitachi will describe the products as
Hitachi Medical of Tokyo will use the RSNA meeting as a springboardin its plan to reenter the nuclear medicine market with directsales and marketing of digital gamma cameras it has manufacturedfor Summit Nuclear. Hitachi will describe the products as works-in-progresson panels in its RSNA booth (SCAN 10/11/95).
Hitachi manufactured the single-head 1024RZ and the dual-headT-22 for Summit, which this year merged with Sopha Medical toform SMV (SCAN 6/21/95). SMV decided to deemphasize the Hitachi-madecameras in favor of systems of its own design.
Hitachi has updated the 1024RZ and T-22 cameras and is resubmittinga 510(k) application for them under the trade name SPECTRADigital.Hitachi is also planning to develop a digital variable-angle dual-headgamma camera for release next year.
In MRI, Hitachi will highlight enhancements to its Airis andStratis platforms, introduced at last year's meeting. A new softwarerelease for the open-configuration Airis and the MRP-7000 0.3-teslaconventional magnet will enable the use of new fast scanning andMR angiography packages. On the 1.5-tesla Stratis, Hitachi willshow phased-array coils and multishot echo-planar imaging as works-in-progress.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
